SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Muñoz P)
 

Search: WFRF:(Muñoz P) > (2000-2004) > A liquid hexavalent...

  • Mallet, E (author)

A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety

  • Article/chapterEnglish2004

Publisher, publication year, extent ...

  • Elsevier BV,2004

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:ddab8886-f1c6-4606-98d3-4dd865d405da
  • https://lup.lub.lu.se/record/899074URI
  • https://doi.org/10.1016/j.vaccine.2003.09.039DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-45341URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:for swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • To reduce the number of injections needed to comply with paediatric vaccination requirements, a liquid, hexavalent vaccine (DTaP-IPV-PRP-T-HBs; Hexavac((R)); Aventis Pasteur MSD) has been developed for primary and booster vaccination of infants and toddlers. In extensive clinical studies, Hexavac((R)) has been shown to be highly immunogenic. Seroconversion or seroprotective titres of antibodies against all antigens were achieved in the majority of infants following a primary series of three doses administered at 1-2-month intervals from 2 months of age. Hexavac((R)) also induced immunologic memory, as evidenced by the anamnestic response to booster vaccination at 12-18 months of age. These responses were comparable with those seen following concomitant administration of Pentavac(TM) (DTaP-IPV//PRP-T) and monovalent hepatitis B vaccine (H-B-Vax(TM) II), and were also within the ranges observed for other relevant licensed vaccines. Clinical studies comparing the immunogenicity of Hexavac((R)) administered at either 2, 3 and 4 months or 2, 4 and 6 months demonstrated that it can be used by either vaccination schedule. A further study also supported the use of primary doses of Hexavac((R)) at 3 and 5 months with a booster at 12 months of age. Hexavac((R)) demonstrated a good reactogenicity and tolerability profile. The most frequently reported adverse events after both primary and booster doses were local reactions of redness and swelling/induration and a systemic response of mild fever, irrespective of the vaccine used for priming. Hexavac((R)) provided immunity against six important childhood diseases with a single injection at each visit. (C) 2003 Elsevier Ltd. All rights reserved.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Belohradsky, BH (author)
  • Lagos, R (author)
  • Gothefors, LeifUmeå universitet,Pediatrik(Swepub:umu)lego0001 (author)
  • Camier, P (author)
  • Carriere, JP (author)
  • Kanra, G (author)
  • Hoffenbach, A (author)
  • Langue, J (author)
  • Undreiner, F (author)
  • Roussel, F (author)
  • Reinert, P (author)
  • Flodmark, Carl-ErikLund University,Lunds universitet,Preventiv pediatrik,Forskargrupper vid Lunds universitet,Preventive Paediatrics,Lund University Research Groups(Swepub:lu)pedi-cfl (author)
  • Stojanov, S (author)
  • Liese, J (author)
  • Levine, MM (author)
  • Munoz, A (author)
  • Schodel, F (author)
  • Hessel, L (author)
  • Umeå universitetPediatrik (creator_code:org_t)

Related titles

  • In:Vaccine: Elsevier BV22:11-12, s. 1343-13571873-25180264-410X

Internet link

Find in a library

  • Vaccine (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view